The Annual and Sustainability Report 2023 is now available digitally in Swedish and an English language version at https://bico.com/investors/financials/financial-reports-and-presentations/.
The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedish.
BICO has for sustainability reasons chosen not to print nor distribute hard copies of the report. Those who are unable to access the report digitally can request a print-out by contacting BICO Investor Relations, [email protected].
For further information, please contact:
Maria Forss, President & CEO, BICO Group AB
Phone: EA Isabella Lundin +46 73 515 99 64
E-mail: [email protected]
Jacob Thordenberg, Chief Financial Officer, BICO Group AB
Phone: +46 73 534 88 84
E-mail: [email protected]
This information is information that BICO Group is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-15 07:00 CET.
About BICO
BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.
The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.
With 46,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 12,000 publications.
Operating through three business areas - Bioprinting, Biosciences and Bioautomation - the BICO Group strives towards the long-term ambition of enabling the reduction of the world's organ shortage and speeding up drug development to create the future of life-saving treatments.
BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com
BICO Group AB